Crizotinib, approved in 2011 by the U.S. Food and Drug Administration (Figure 1), is the first drug targeting EML4-ALK for first-line treatment of EML4-ALK-expressing NSCLC patients.14 Here, ALK is linked to non-small cell lung carcinoma.